|
|
| Line 1: |
Line 1: |
| {{drugbox
| |
| | IUPAC_name = 1-(1-adamantyl)ethanamine
| |
| | image = Rimantadine.png
| |
| | width = 84
| |
| | CAS_number = 13392-28-4
| |
| | ATC_prefix = J05
| |
| | ATC_suffix = AC02
| |
| | PubChem = 5071
| |
| | DrugBank = APRD01219
| |
| | C = 12 |H = 21 |N = 1
| |
| | molecular_weight = 179.302 [[Gram|g]]/[[Mole (unit)|mol]]
| |
| | bioavailability = well absorbed
| |
| | protein_bound = 40%
| |
| | metabolism = [[Liver|Hepatic]] [[hydroxylation]] and [[glucuronidation]]
| |
| | elimination_half-life = 25.4 ± 6.3 hours
| |
| | excretion = [[Kidney|Renal]]
| |
| | pregnancy_category = C <small>([[United States|U.S.]])</small>
| |
| | legal_status = ℞-only <small>(U.S.)</small>
| |
| | routes_of_administration = Oral
| |
| }}
| |
| {{SI}}
| |
| __NOTOC__ | | __NOTOC__ |
| | {{Rimantadine}} |
| | {{CMG}} |
|
| |
|
| | ==Overview== |
| | '''Rimantadine''' ([[International Nonproprietary Name|INN]], sold under the trade name '''Flumadine''') is an orally administered [[antiviral drug]]used to treat, and in rare cases prevent, [[Influenzavirus A]] infection. When taken within one to two days of developing symptoms, rimantadine can shorten the duration and moderate the severity of influenza. It is a derivate of [[adamantane]], like a similar drug [[amantadine]]. It was approved by the [[Food and Drug Administration]] (FDA) in 1994. |
|
| |
|
| '''For patient information, please click [[Rimantadine (patient information)|here]]'''
| | ==Category== |
| | Antiviral |
| | ==US Brand Names== |
| | Flumadine<sup>®</sup> |
| | ==FDA Package Insert== |
|
| |
|
| '''Rimantadine''' ([[International Nonproprietary Name|INN]], sold under the trade name '''Flumadine''') is an orally administered [[antiviral drug]] used to treat, and in rare cases prevent, [[Influenzavirus A]] infection. When taken within one to two days of developing symptoms, rimantadine can shorten the duration and moderate the severity of influenza. It is a derivate of [[adamantane]], like a similar drug [[amantadine]]. It was approved by the [[Food and Drug Administration]] (FDA) in 1994. | | ''' [[Rimantadine description|Description]]''' |
| | '''| [[Rimantadine clinical pharmacology|Clinical Pharmacology]]''' |
| | '''| [[Rimantadine microbiology|Microbiology]]''' |
| | '''| [[Rimantadine indications and usage|Indications and Usage]]''' |
| | '''| [[Rimantadine contraindications|Contraindications]]''' |
| | '''| [[Rimantadine warnings and precautions|Warnings and Precautions]]''' |
| | '''| [[Rimantadine adverse reactions|Adverse Reactions]]''' |
| | '''| [[Rimantadine drug interactions|Drug Interactions]]''' |
| | '''| [[Rimantadine overdosage|Overdosage]]''' |
| | '''| [[Rimantadine clinical studies|Clinical Studies]]''' |
| | '''| [[Rimantadine dosage and administration|Dosage and Administration]]''' |
| | '''| [[Rimantadine how supplied|How Supplied]]''' |
| | '''| [[Rimantadine labels and packages|Labels and Packages]]''' |
|
| |
|
| ==Mechanics== | | ==Mechanism of Action== |
|
| |
|
| Scientists do not understand why rimantadine works, but believe it inhibits influenza's [[Virus#Viral replication|viral replication]], possibly by preventing the uncoating of the virus's protective shells, which are the [[Virus#Viral structure|envelope and capsid]]. Genetic studies suggest that the virus [[M2 protein]], an [[ion channel]] specified by virion M2 [[gene]], plays an important role in the susceptibility of influenza A virus to inhibition by rimantadine. Resistance to rimantadine can occur as a result of an amino acid substitutions at certain locations in the transmembrane region of M2. This prevents binding of the antiviral to the channel.
| | ==References== |
| | {{Reflist|2}} |
|
| |
|
| ==Drug interactions==
| | [[Category:Antiviral]] |
| | | [[Category:Wikinfect]] |
| Taking [[acetaminophen]] ([[Tylenol]]) or [[aspirin]] while taking rimantadine is known to reduce the body's uptake of rimantadine by approximately 12%.[http://www.fda.gov/cder/drug/antivirals/influenza/flumadine.htm] [[Cimetidine]] also affects the body's uptake of rimantadine.
| |
| | |
| ==Adverse effects==
| |
| | |
| Rimantadine can produce [[gastrointestinal]] and [[central nervous system]] [[Adverse effect (medicine)|adverse effects]]. Studies have shown it produces fewer side effects than other anti-viral influenza treatments. Approximately 6% of patients (compared to 6% of patients taking a placebo) reported side effects.[http://www.cdc.gov/flu/professionals/treatment/side-effects.htm] Common side effects include:
| |
| | |
| *[[nausea]]
| |
| *upset stomach
| |
| *nervousness
| |
| *tiredness
| |
| *lightheadedness
| |
| *trouble sleeping
| |
| *difficulty concentrating
| |
| | |
| ==Other Uses==
| |
| | |
| Rimantadine, like its antiviral cousin [[amantadine]], possesses some NMDA antagonistic properties and is used as an antiparkinsonic drug (ie, in the treatment of [[Parkinson's Disease]]). However, neither rimantadine nor amantadine are preferred agents for this therapy and are generally reserved for cases of the disease which are less responsive to front-line treatments.
| |
| | |
| ==External links==
| |
| | |
| *[http://www.fda.gov/bbs/topics/ANSWERS/ANS00530.html U.S. FDA press release announcing rimantadine's approval]
| |
| *[http://www.fda.gov/cder/drug/antivirals/influenza/flumadine.htm U.S. Center for Drug Evaluation and Research rimantadine description]
| |
| *[http://www.nlm.nih.gov/medlineplus/druginfo/medmaster/a698029.html U.S. NIH rimantadine description]
| |
| *[http://www.cdc.gov/flu/professionals/treatment/index.htm U.S. CDC flu anti-viral treatment information]
| |
| | |
| {{Antivirals}}
| |
| {{Influenza}}
| |
| | |
| | |
| | |
| [[es:Rimantadina]]
| |
| [[fr:Rimantadine]]
| |
| [[th:ไรแมนตาดีน]]
| |
| [[zh:金刚乙胺]]
| |
| | |
| {{WikiDoc Help Menu}}
| |
| {{WikiDoc Sources}}
| |
| | |
| [[Category:Anti-influenza agents]]
| |
| [[Category:Influenza]] | |
| [[Category:Infectious disease]] | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Rimantadine (INN, sold under the trade name Flumadine) is an orally administered antiviral drugused to treat, and in rare cases prevent, Influenzavirus A infection. When taken within one to two days of developing symptoms, rimantadine can shorten the duration and moderate the severity of influenza. It is a derivate of adamantane, like a similar drug amantadine. It was approved by the Food and Drug Administration (FDA) in 1994.
Category
Antiviral
US Brand Names
Flumadine®
FDA Package Insert
Description
| Clinical Pharmacology
| Microbiology
| Indications and Usage
| Contraindications
| Warnings and Precautions
| Adverse Reactions
| Drug Interactions
| Overdosage
| Clinical Studies
| Dosage and Administration
| How Supplied
| Labels and Packages
Mechanism of Action
References